Sorafenib in the Management of Metastatic Renal Cell Carcinoma

Abstract

Until the advent targeted therapies, Interferon and Interleukin represented the standards of care for patients with metastatic renal cell carcinoma (mRCC). Over the past 2 years, five randomized placebo-controlled trials demonstrated the efficacy of five novel targeted therapies in mRCC patients.1-5 First, Motzer et al. (n=750) showed that Sunitinib improves median progression free survival (PFS) in previously untreated patients, relative to Interferon, from 5 to 11 months (hazard ratio HR=0.42; p